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Sunlight and psoralen and ultraviolet A (PUVA) are risk factors for the development of squamous cell carcinoma
(SCC) and, to a lesser extent, basal cell carcinoma (BCC). Ultraviolet B (UVB) therapy, used for the treatment of
psoriasis, might also increase the risk of these tumors. We studied the relation of skin cancer incidence to UVB use
among 1380 adult subjects enrolled in a long-term safety trial of PUVA therapy. We used negative binomial re-
gression models to quantify the association between UVB and the development of non-melanoma skin cancer
(NMSC), controlling for known confounders. High UVB exposure (X300 treatments vs o300 treatments) was as-
sociated with a modest but significant increase in SCC (adjusted incidence rate ratio (IRR)¼ 1.37, 95% conﬁdence
interval (CI)¼ 1.03–1.83) and BCC (adjusted IRR¼ 1.45, 95% CI¼ 1.07–1.96) risk. Among patients with o100 PUVA
treatments, high UVB exposure was significantly associated with the development of SCC (adjusted IRR¼ 2.75, 95%
CI¼ 1.11–6.84) and BCC (adjusted IRR¼ 3.00, 95% CI¼ 1.30–6.91) on body sites typically exposed to UVB therapy
but not on chronically sun-exposed sites typically covered during therapy. For adults with high UVB exposure
levels, UVB confers a modest increase in NMSC risk, much less than that observed with PUVA. Therefore, UVB
remains a relatively low-risk treatment for psoriasis.
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Sun exposure, in particular solar ultraviolet B (UVB), is the
leading environmental risk factor for the development of
non-melanoma skin cancer (NMSC) in humans (Vitasa et al,
1990; Rosso et al, 1996; Armstrong and Kricker, 2001). In
mice, artificially administered UVB induces skin tumors
(Wulf et al, 1994). Although UVB is widely used as a treat-
ment for moderate-to-severe psoriasis and other skin con-
ditions, the carcinogenicity of therapeutic UVB in humans is
not well quantified (Boer et al, 1980; Anderson et al, 1984).
Based on the emission spectra of broadband UVB lamps
and the sun, Nachtwey and Rundel (1981) estimated that
broadband UVB might be twice as carcinogenic per minimal
erythemal dose as the sun. Prior studies of the risks asso-
ciated with UVB have differed from each other in study de-
sign, size of the study population, length of follow-up,
degree of exposure, and results. Although it appears logical
that long-term therapeutic UVB might cause skin cancers,
the magnitude of this risk is controversial (Studniberg and
Weller, 1993; Pasker-de Jong et al, 1999).
An analysis from the PUVA follow-up study cohort that
included data up to August 31, 1989, failed to detect any
appreciable risk of NMSC associated with UVB therapy in
this cohort (Stern and Laird, 1994). Since that time, the
PUVA study subjects have been followed for an additional
14 y, have accumulated more than 100,000 additional UVB
treatments, and additional time from exposure to the pos-
sible development of tumors has elapsed. Thus, we are now
able to give a more complete analysis of the risks of UVB
therapy, including the effect of UVB exposure on subjects
with low exposure to PUVA and the effect of UVB at dif-
ferent anatomic sites. By performing a subanalysis limited
to patient years with less than 100 PUVA treatments and
stratified according to anatomic site, we are able to focus
on tumors that are most likely related to UVB use rather
than PUVA use or sun exposure.
Results
Follow-up and tumors As of August 2003, of the 1380
originally enrolled patients, 609 were still followed, 521 had
died, and 250 had been lost to follow-up or had withdrawn
from the study. The number of deaths was consistent with
the number expected for a population that is predominantly
male with an average age of 44 y in 1975. All observations
from enrollment to last completed interview, last reported
tumor, or death were included in this report, and totaled
27,928 patient years. From enrollment to the last follow-up
interview in 2003, 2528 invasive squamous cell carcinomas
(SCC) among 329 (23.8%) patients and 1566 basal cell
carcinomas (BCC) among 305 (22%) patients have been
Abbreviations: BCC, basal cell cancer; CI, confidence interval; IRR,
incidence rate ratio; NMSC, nonmelanoma skin cancer; PUVA,
psoralen and ultraviolet A; SCC, squamous cell cancer; UVB, ul-
traviolet B
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documented by pathology report. The low-dose PUVA
group (o100 treatments), whose follow-up totaled 11,992
(43%) patient years, developed 197 (8%) invasive SCC
among 54 patients and 256 (16%) BCC among 75 patients.
Table I presents tumors and tumor incidence by categories
of UVB and PUVA exposure. A higher incidence of SCC and
BCC is seen in subjects with higher UVB exposure, higher
PUVA exposure, and in males. Online Table S1 provides
additional data on tumor incidences by gender and by level
of UVB for the low-dose PUVA group. Online Table S2 pro-
vides the anatomic distribution of tumors for the entire co-
hort and the low-dose PUVA group. Most SCC (72%)
occurred on the trunk, legs, and buttocks, whereas more
BCC (59%) were found on the head and neck.
UVB exposure over time For the entire cohort, 465,341
lifetime UVB treatments have been reported among 1154
patients. At the time of first follow-up in 1977, 973 patients
reported past UVB use. An additional 181 patients first re-
ported UVB use after 1977. Among treated subjects, the
average number of UVB treatments reported was 403, the
median was 200, the range was 1–6666, and the interquar-
tile range was 58–493. Nearly two-thirds of all UVB expo-
sure occurred after 1977. Reported UVB use for this cohort
steadily increased from 172,329 treatments among 973 pa-
tients in 1977 to 465,341 treatments among 1154 in 2002
(Fig 1).
Overall results
SCC Table II presents the univariate and multivariate risk
analysis for the development of at least one SCC in a given
year for the entire cohort. The univariate model shows a
significant association between high levels of UVB exposure
and increased risk of SCC (incidence rate ratio (IRR)¼ 1.42,
95% confidence interval (CI)¼1.08–1.86). As expected,
PUVA exposure was the strongest predictor of SCC risk.
Other significant predictors of SCC risk in the univariate
model were male gender, types I–II skin, southern resi-
dence, high cyclosporin exposure, and high methotrexate
Table I. Skin tumor incidence by tumor type and level of exposure to UVB and PUVA
Variable Person years (%)
Number of
tumors (%)
Tumor incidence
per 100,000
person years
Number of
incident
tumorsa (%)
Tumor incidence
per 100,000 person
years, if only including
incident tumors
Squamous cell carcinoma (SCC)
UVB
Low (o300) 20,921 (74.9) 1538 (60.8) 7351 696 (63.0) 3327
High (X300) 7007 (25.1) 990 (39.2) 14,129b 408 (37.0) 5823b
PUVA
Low (o100) 11,922 (42.7) 197 (7.8) 1652 118 (10.7) 990
Not low (X100) 16,006 (57.3) 2331 (92.2) 14,563b 986 (89.3) 6160b
Basal cell carcinoma (BCC)
UVB
Low (o300) 20,921 (74.9) 880 (56.2) 4206 511 (61.8) 2443
High (X300) 7007 (25.1) 686 (43.8) 9790b 316 (38.2) 4510b
PUVA
Low (o100) 11,922 (42.7) 256 (16.3) 2147 148 (17.9) 1241
Not low (X100) 16,006 (57.3) 1310 (83.7) 8184b 679 (82.1) 4242b
aIncident tumor: can only equal 0 or 1 for a single person in a given year because it represents the first tumor of a given cell type in a given year. For
example, if an individual had three SCC in 1 y, his total number of SCC for that year¼3, but his number of incident tumors equals one. In this way, we
limit the influence of outliers, i.e. those rare individuals who develop a large number of tumors per year.
bpo0.05 compared with incidence of other stratum.
UVB, ultraviolet B; PUVA, psoralen and ultraviolet A.
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1154
1143
1133
1112
1058
973
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
500000
1977 1982 1987 1992 1997 2002
Year
To
ta
l n
um
be
r o
f U
VB
 tr
ea
tm
en
ts
 fo
r a
ll 
Su
bje
cts
Figure1
Ultraviolet B (UVB) use among cohort members over time. The
histogram shows the total number of UVB treatments ever received
(bars) as a function of calendar year (x-axis). The values above the bars
represent the number of cohort members in that year who had a history
of ever using UVB.
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exposure, all of which were associated with increased risk
of SCC by approximately 50%–100%. In the multivariate
model, after adjusting for all known carcinogenic risk mod-
ifiers in this population, a high level of UVB exposure was
significantly associated with SCC risk (IRR¼1.37, 95%
CI¼ 1.03–1.83, p for trend o0.001). Except for cyclosporin
exposure, the risk factors that were significantly associated
with the development of at least one SCC in the univariate
model remained significant in the multivariate model.
Site-specific analysis In an analysis of SCC by anatomic
location (Table IIIa), the risks of UVB therapy were greater
on the torso, buttocks, and legs, which are rare to intermit-
tently exposed to the sun, but tend to be exposed during
phototherapy (IRR¼1.48, 95% CI¼ 1.06–2.07). A high level
of UVB use was not significantly related to the development
of SCC on chronically sun-exposed sites such as the head
and neck, which are usually covered during phototherapy
(IRR¼1.12, 95% CI¼ 0.70–1.79). A subanalysis limited to
Table II. Univariate and multivariate analysis of potential risk factors associated with the development of
SCC for the entire cohorta
Univariate modelb Multivariate modelc
IRR 95% CI
p-value
for trend IRR 95% CI
p-value
for trendd
No. of lifetime UVB treatments o0.001 o0.001
o300e 1 1
X300 1.42 1.08–1.86 1.37 1.03–1.83
No. of lifetime PUVA treatments o0.001 o0.001
o100e 1 1
100–199 2.34 1.48–3.70 2.36 1.51–3.68
200–299 4.15 2.59–6.66 4.14 2.64–6.50
300–399 5.93 3.59–9.79 5.54 3.38–9.09
400–499 10.25 6.26–16.78 11.05 6.88–17.76
X500 10.47 6.28–17.45 10.81 6.76–17.29
Gender 0.007 0.005
Womene 1 1
Men 1.57 1.13–2.19 1.62 1.19–2.20
Skin type 0.010 o0.001
III–IVe 1 1
I–II 1.46 1.09–1.95 1.76 1.33–2.31
Region at time of enrollment 0.654 0.003
Northe 1 1
Middle 0.81 0.56–1.17 0.94 0.68–1.30
South 1.11 0.81–1.51 1.84 1.36–2.49
High methotrexate exposure
(X36 mo) compared with low
1.95 1.51–2.51 o0.001 1.66 1.32–2.08 o0.001
High tar exposure (X45 mo)
compared with low
1.21 0.89–1.65 0.216 1.02 0.75–1.39 0.926
High cyclosporin exposure
(X3 mo in a given year until
5 y after last use, compared
with low exposure)
2.08 1.17–3.69 0.013 1.43 0.88–2.31 0.048
Year with high retinoid exposure
(X26 wk in a given year,
compared with low exposure)
1.20 0.77–1.87 0.427 0.88 0.57–1.35 0.725
aEstimates of the incident rate ratios were obtained from univariate and multivariate negative binomial regression models.
bUnivariate analysis adjusted for age and year.
cIn addition to the variables listed, the multivariate model adjusted for age and year.
dThe analysis for p for trend considered age, year, UVB, PUVA, and residence as continuous variables and gender, skin type, methotrexate, tar,
cyclosporin, and retinoid use as categorical variables.
eThis group served as the reference group.
SCC, squamous cell carcinoma; IRR, incidence rate ratio; CI, confidence interval; UVB, ultraviolet B; PUVA, psoralen and ultraviolet A.
UVB FOR NON-MELANOMA SKIN CANCER RISK 507124 : 3 MARCH 2005
patient years with total PUVA treatments o100 (Table IIIb)
showed that the relative risk of SCC among subjects with
high UVB (X300) but low PUVA exposure appears greater
on rare to intermittently sun-exposed parts of the body
(IRR¼2.75, 95% CI¼ 1.11–6.84) compared with chronically
sun-exposed sites (IRR¼0.81, 95% CI¼ 0.34–1.93).
BCC Table IV presents the univariate and multivariate risk
analysis for the development of at least one BCC in a given
year for the entire cohort. In the univariate analysis, high
UVB exposure was associated with a significant increase in
the risk of BCC (IRR¼ 1.53, 95% CI¼1.15–2.03). Other
significant predictors of BCC risk in the univariate model
were PUVA exposure, the male gender, high level of tar
exposure, and high level of methotrexate exposure. In the
multivariate analysis, a high level of UVB exposure remained
a significant predictor of BCC risk (IRR¼1.45, 95%
CI¼ 1.07–1.96, p for trend¼ 0.025). The level of PUVA ex-
posure was also associated with BCC risk, but it was a
more modest predictor for BCC risk than it was for SCC risk
(see Table II). Other predictors of BCC risk included male
gender and southern residence. Methotrexate and tar,
which were significant predictors of BCC risk in the univari-
ate analysis, were not independently significant in the mul-
tivariate analysis.
Site-specific analysis In an analysis of BCC by anatomic
location (Table Va), the relative risks of UVB therapy were
greater on the torso, buttocks, and legs, which are rare to
intermittently exposed to the sun, but tend to be exposed
during phototherapy (IRR¼ 1.72, 95% CI¼1.13–2.61). A
high level of UVB use was not related to the development of
BCC on chronically sun-exposed sites such as the head
and neck, which are usually covered during phototherapy
(IRR¼1.31, 95% CI¼ 0.91–1.89). A subanalysis limited to
patient years with total PUVA treatments o100 (Table Vb)
showed that the risk of BCC among subjects with high UVB
(X300) but low PUVA exposure appears greater on rare to
intermittently sun-exposed parts of the body (IRR¼ 3.00,
95% CI¼ 1.30–6.91) compared with chronically sun-ex-
posed sites (IRR¼ 1.38, 95% CI¼0.80–2.39).
Attributable risk Based on the IRR estimated in the multi-
variate analysis, we calculated the adjusted attributable risk
Table III. Association of high UVB on sun exposed versus non-sun-exposed sites for SCC
(a) All person years
SCC on sun-exposed area univariatea SCC on sun-exposed area multivariateb
IRR 95% CI IRR 95% CI
UVB
o300 treatments 1 1
X300 1.06 0.68–1.66 1.12 0.70–1.79
SCC on non-sun-exposed area univariatea SCC on non-sun-exposed area multivariateb
IRR 95% CI IRR 95% CI
UVB
o300 treatments 1 1
X300 1.58 1.15–2.17 1.48 1.06–2.07
(b) Low dose PUVA group
SCC on sun-exposed area univariatea SCC on sun-exposed area multivariatec
IRR 95% CI IRR 95% CI
UVB
o300 treatments 1 1
X300 0.97 0.33–2.81 0.81 0.34–1.93
SCC on non-sun-exposed area univariatea SCC on non-sun-exposed area multivariatec
IRR 95% CI IRR 95% CI
UVB
o300 treatments 1 1
X300 2.36 0.92–6.05 2.75 1.11–6.84
aUnivariate analysis adjusted for age and year.
bMultivariate analysis adjusted for age, year, level of PUVA exposure, gender, skin type, geographic residence, and use of methotrexate, tar,
cyclosporin, and retinoids.
cBecause frequency of use of these therapies was o1% of total patient years, cyclosporin, and retinoid use were excluded from the multivariate
analysis in the low PUVA group. In the low PUVA group, PUVA use was divided into three categories of exposure: 0–33, 34–66, and 67–99 treatments.
UVB, ultraviolet B; SCC, squamous cell carcinoma; IRR, incidence rate ratio; CI, confidence interval; PUVA, psoralen and ultraviolet A.
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associated with a high degree of UVB exposure. Among
those patients who were exposed to high levels of UVB
therapy, about 27% of SCC and 31% of BCC were attrib-
utable to receiving high levels of UVB (X300 treatments).
On rare to intermittently sun-exposed body sites where the
incidence of tumors is much lower among those with low-
dose PUVA exposure, approximately 64% of SCC and 67%
of BCC in this subgroup were attributable to exposure to
high levels of UVB.
Discussion
Risk of SCC and BCC Our analysis indicates that high
levels of UVB exposure are associated with modest but
significantly increased risk of both SCC and BCC tumors.
Others have estimated that psoriasis patients on mainte-
nance UVB therapy receive a mean annual UVB dose al-
most twice as high as controls with an outdoor occupation
and would be expected to have a higher incidence of NMSC
Table IV. Univariate and multivariate analysis of potential risk factors associated with the development
of BCC for the entire cohorta
Univariate modelb Multivariate modelc
IRR 95% CI
p-value
for trend IRR 95% CI
p-value
for trendd
No. of lifetime UVB treatments 0.024 0.025
o300e 1 1
X300 1.53 1.15–2.03 1.45 1.07–1.96
No. of lifetime PUVA treatments o0.001 o0.001
o100e 1 1
100–199 1.87 1.23–2.82 1.80 1.21–2.70
200–299 2.07 1.33–3.24 2.00 1.32–3.03
300–399 3.07 1.90–4.95 2.81 1.75–4.51
400–499 3.00 1.73–5.20 2.93 1.73–4.98
X500 3.73 2.21–6.30 3.65 2.21–6.03
Gender o0.001 o0.001
Womene 1 1
Men 1.80 1.35–2.40 1.80 1.35–2.40
Skin type 0.993 0.485
III–IVe 1 1
I–II 1.00 0.74–1.36 1.15 0.85–1.55
Region at time of enrollment 0.417 0.041
Northe 1 1
Middle 1.02 0.69–1.52 1.08 0.75–1.57
South 1.15 0.83–1.60 1.43 1.06–1.95
High methotrexate exposure
(X36 mo) compared with low
1.39 1.03–1.89 0.031 1.24 0.92–1.67 0.095
High tar exposure (X45 mo)
compared with low
1.45 1.09–1.95 0.012 1.28 0.93–1.76 0.075
High cyclosporin exposure
(X3 mo in a given year until
5 y after last use, compared
with low exposure)
1.88 0.87–4.04 0.108 1.38 0.64–2.99 0.284
Year with high retinoid exposure
(X26 wk in a given year,
compared with low exposure)
1.45 0.89–2.36 0.131 1.28 0.80–2.04 0.261
aEstimates of the incident rate ratios were obtained from univariate and multivariate negative binomial regression models.
bUnivariate analysis adjusted for age and year.
cIn addition to the variables listed, the multivariate model adjusted for age and year.
dThe analysis for p for trend considered age, year, UVB, PUVA, and residence as continuous variables and gender, skin type, methotrexate, tar,
cyclosporin, and retinoid use as categorical variables.
eThis group served as the reference group.
BCC, basal cell carcinoma; IRR, incidence rate ratio; CI, confidence interval; UVB, ultraviolet B; PUVA, psoralen and ultraviolet A.
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tumors (Schothorst et al, 1985). Our results are also con-
sistent with epidemiological studies linking sunlight expo-
sure and the risk of NMSC. In the univariate and multivariate
analyses for both SCC and BCC, we observed an increased
risk associated with high levels of UVB exposure. When we
considered UVB as a continuous variable, exposure to a
higher number of treatments was a significant predictor of
SCC and BCC risk. Controlling for possible confounders,
we estimated that in comparison with someone with low-
dose UVB exposure, high-dose UVB exposure (X300 treat-
ments) increases the risk of developing an SCC or BCC in a
given year by about 40%. The attributable risk associated
with high UVB exposure was about 30% for both SCC and
BCC. Therefore, of the 2528 SCC in the entire cohort, we
estimate that about 270 SCC (11%) might have been pre-
vented if no patient had been exposed to high levels of
UVB. For BCC, about 210 of the 1566 cases (13%) might
have been avoided if no one in the cohort had received high
levels of UVB. Thus, among members of this cohort, ap-
proximately one less SCC and one less BCC would have
occurred per one hundred individuals per year had no
member received high levels of UVB therapy.
Risk varies with anatomic site In addition to UVB, this
cohort has been exposed to other carcinogens such as
sunlight and PUVA. In general, ambient sun exposure is
greatest on the head and neck whereas it is relatively low on
the trunk, buttocks, and lower extremities. Thus, to under-
stand the relative risk of therapeutic UVB in areas with and
without substantial exposure to sunlight, we separately
analyzed tumors on the head and neck (i.e., chronically sun
exposed) and the trunk, buttocks, and lower extremities
(i.e., rare to intermittently sun exposed). Although the trunk,
buttocks, and legs are not chronically sun exposed, they are
usually exposed in the phototherapy unit and thus, we hy-
pothesized that the risks of therapeutic UVB exposure
would be more detectable on these areas. Our results are
consistent with this hypothesis; greatest risks associated
with high levels of UVB exposure were observed on areas
usually exposed to UVB but not sun light.
Separating the effects of UVB and PUVA The cohort
subjects also differ from each other in the quantity of PUVA
treatments received. Some have received many treatments
whereas others remain relatively unexposed to PUVA. PUVA
TableV. Association of high UVB on sun exposed versus non-sun-exposed sites for BCC
(a) All person years
BCC on sun-exposed area univariatea BCC on sun-exposed area multivariateb
IRR 95% CI IRR 95% CI
UVB
o300 treatments 1 1
X300 1.37 0.96–1.94 1.31 0.91–1.89
BCC on non-sun-exposed area univariatea BCC on non-sun-exposed area multivariateb
IRR 95% CI IRR 95% CI
UVB
o300 treatments 1 1
X300 1.91 1.30–2.82 1.72 1.13–2.61
(b) Low dose PUVA group
BCC on sun-exposed area univariatea BCC on sun-exposed area multivariatec
IRR 95% CI IRR 95% CI
UVB
o300 treatments 1 1
X300 1.47 0.62–3.50 1.38 0.80–2.39
BCC on non-sun-exposed area univariatea BCC on non-sun-exposed area multivariatec
IRR 95% CI IRR 95% CI
UVB
o300 treatments 1 1
X300 3.02 1.26–7.26 3.00 1.30–6.91
aUnivariate analysis adjusted for age and year.
bMultivariate analysis adjusted for age, year, level of PUVA exposure, gender, skin type, geographic residence, and use of methotrexate, tar,
cyclosporin, and retinoids.
cBecause frequency of use of these therapies was o1% of total patient years, cyclosporin and retinoid use were excluded from the multivariate
analysis in the low PUVA group. In the low PUVA group, PUVA use was divided into three categories of exposure: 0–33, 34–66, and 67–99 treatments.
UVB, ultraviolet B; BCC, basal cell carcinoma; IRR, incidence rate ratio; CI, confidence interval; PUVA, psoralen and ultraviolet A.
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substantially increases the risk of SCC, especially at very
high levels of exposure, and may overshadow the effects of
lesser risk modifiers such as UVB. Therefore, in addition to
stratifying the tumors according to anatomic site, we also
limited the subanalysis to only include person years with
total PUVA treatments o100. The risk of SCC and BCC on
rare to intermittently sun-exposed sites among those with
low PUVA exposure was approximately three times higher
for those who had high compared with low amounts of UVB
exposure. Despite this large increase in relative risk, how-
ever, the absolute increase in risk was low because this
group had relatively low baseline tumor risk. About two-
thirds of SCC and BCC in this subgroup were attributable to
a high level of UVB exposure; we estimate that about 29
SCC and 19 BCC on these sites might have been prevented
over approximately 12,000 person years. Thus, among 1000
individuals treated with low-dose PUVA, approximately 2.4
fewer SCC and 1.6 fewer BCC would have occurred per
year on the trunk, buttocks, or lower extremities had no one
received high levels of UVB therapy.
UVB versus PUVA risk Although UVB is a significant risk
factor for NMSC, comparable numbers of UVB treatments
have far less associated carcinogenic risk than PUVA ther-
apy. The ratio of attributable risk per treatment of PUVA and
per treatment of UVB is about 7 for both SCC and BCC,
suggesting that the carcinogenic risk of a single PUVA
treatment is about seven times greater than a single UVB
treatment. The magnitude of increased NMSC risk associ-
ated with high UVB exposure is similar to the increased risk
that is seen among males, those with type 1 or 2 skin, or
those living in southern versus northern states.
Additional analyses We performed several data analyses
in addition to the main results presented above. In addition
to using the endpoint of one SCC and one BCC in a year, we
separately analyzed our data with the total number of SCC
and BCC in a given year as the endpoint. When using this
endpoint, the IRR for the effect of UVB were generally
higher but the 95% CI overlapped (results not shown). We
present the results from the one tumor per year analysis
rather than the total tumors per year analysis since the one
tumor per year analysis is consistent with the methodolog-
ical approach used in previously published reports from this
cohort and results in IRR estimates that tend to be more
conservative. A separate analysis of subjects who were
moderately exposed to UVB (100–299 treatments) showed
that they had no significant increase in the risk of develop-
ing SCC or BCC compared with those exposed to 1–99
UVB treatments.
Strengths and Limitations
The strengths of this study include its prospective design,
its length of follow-up, and the high amount of therapeutic
UVB exposure among subjects. To our knowledge, this
study is the largest prospective analysis of the relationship
between therapeutic UVB and NMSC risk. In addition to
documenting previous UVB exposures at first follow-up, this
cohort has been interviewed 21 times over a 28-y period
and additional exposures have been prospectively docu-
mented. Subjects received over two-thirds of their total
lifetime UVB exposure prior to 1987, allowing more than 15
y of observation for tumors to develop after substantial UVB
exposure. In addition, members of this cohort have had
significant amounts of UVB exposure, enabling us to detect
small increases in risk that result from a high degree of
exposure. As of last follow-up, 442 (32%) cohort members
have been exposed to a high dose of UVB (X300 treat-
ments). For the entire cohort, UVB treatments outnumber
PUVA treatments by nearly 2:1 (465,341 vs 275,524). We
used conservative measures of tumor incidence by exclud-
ing SCC in situ and keratoacanthomas, by requiring that all
tumors have pathological confirmation, and by including
only the first tumor in a given year in the analysis. In ad-
dition, for the univariate and multivariate analyses, we used
the negative binomial regression, a variant of the Poisson
regression that takes into account the higher risk of a sub-
sequent skin cancer in an individual with a prior tumor. In
general, results based on the negative binomial regression
will have wider CI and higher p-values than the results ob-
tained from the Poisson regression, and are therefore more
conservative risk estimates (Glynn and Buring, 1996).
Until now, studies of NMSC risk among patients treated
with UVB therapy have reported on groups with limited fol-
low-up and relatively low exposure to UVB. For example, a
1980 analysis of UVB use in this cohort showed an in-
creased risk of NMSC with UVB therapy, but this risk was
not apparent in later analyses of this cohort (Stern et al,
1980; Stern and Laird, 1994). Other studies have been un-
able to detect a significant risk associated with UVB ther-
apy, but these studies have been retrospective, small (o300
patients), had limited follow-up (o8500 patient years), and
documented limited UVB exposure (Pittelkow et al, 1981;
Larko and Swanbeck, 1982). Our current results suggest
that the risks of UVB therapy are only significant after very
high cumulative exposure and after sufficient time has
elapsed from exposure for the development of tumors.
Broadband UVB was our cohort’s dominant type of UVB
exposure. Until 1998, broadband was the predominant type
of UVB therapy available in the United States, and it is still
widely used for the treatment of psoriasis (personal com-
munication with Ms Heather Herbig, Sales Consultant at
National Biological Corporation on March 29, 2004). We did
not have information that permitted the quantification and
separate analysis of the different types of UVB that are
currently utilized to treat patients, such as narrowband UVB
(Young, 1995). Our results, however, are relevant for as-
sessing the risks and benefits of currently available psoria-
sis therapies and predicting the risk of past exposures.
A limitation of this study and other studies of UV carcin-
ogenesis is the imprecise quantification of sun exposure.
The within-group variation in the relative risks associated
with high levels of reported sun exposure underscores the
difficulties of using recall of sun exposure history to quantify
the risks of solar radiation (Vitaliano and Urbach, 1980;
Rosso et al, 1996; Kennedy et al, 2003). As has been done in
other epidemiological studies, we used age and geographic
residence as surrogate markers of cumulative sun exposure
(Holman et al, 1984; Grodstein et al, 1995; Van Dam et al,
1999). The increased NMSC risk associated with living in
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southern versus northern states in our analysis was com-
parable with other published reports (Grodstein et al, 1995;
Van Dam et al, 1999). An additional limitation of this study is
the heterogeneity of the PUVA cohort population. This co-
hort includes patients who have been exposed to multiple
therapeutic agents, such as PUVA, methotrexate, cyclos-
porin, and retinoids, all of which have been shown to impact
the risk of SCC, and in some cases BCC (Marcil and Stern,
2001; Nijsten and Stern, 2003a, b). We accounted for all
known risk factors in this population by including them in
the multivariate analyses and by conducting subanalyses
that limited the effects of competing risks. In addition, we
tested for interaction between UVB and PUVA therapy,
which was not significantly associated with tumor risk.
Lastly, the prospective cohort study design has inherent
limitations and potential biases. Misclassification bias and
recall bias have been limited by conducting interviews every
1–3 y, lessening the likelihood that a patient will greatly
misreport their recent use of psoriasis therapies. Exposures
have been documented prospectively and only tumors di-
agnosed pathologically have been included in the analysis.
Conclusion
These results demonstrate that high UVB exposure levels
(X300 treatments) confer a modest but significant increase
in NMSC risk in adults. The increase in relative risk is most
apparent among individuals not previously treated with
large amounts of PUVA therapy on anatomic sites typically
exposed during phototherapy, but only rare to intermittently
exposed to sunlight. But since the underlying tumor inci-
dence in this low-risk population on these anatomic sites is
relatively small, even in this circumstance, the increased risk
of NMSC does not translate into a substantially higher ab-
solute incidence of tumors. Thus, the modest risks asso-
ciated with UVB therapy must be weighed in the context of
a patient’s underlying skin cancer risk and against the ben-
efits of therapy. Overall, UVB therapy is substantially less
carcinogenic than PUVA therapy. Our data should provide
substantial reassurance to patients and their treating phy-
sicians that long-term treatment with UVB is reasonably
safe. Therefore, this often highly effective treatment should
continue to be considered a primary treatment option for
patients with moderate-to-severe psoriasis (Anderson et al,
1984; Dawe et al, 2002).
Methods
Background The PUVA follow-up study is a collaborative pro-
spective cohort safety study of 1380 adult patients with moderate-
to-severe psoriasis first treated in 1975–1976 with PUVA therapy,
who have been followed to the present day. Details of the prior
hypotheses and procedures of the study are presented in the on-
line supplement. The institutional review boards at the participating
centers approved the study and all patients provided written in-
formed consent at the time the study was initiated. The study was
approved by the Beth Isreal Deaoness Medical Center Institutional
Review and Privacy Board and was performed in adherence to
the Declaration of Helsinki Guidelines. At the time of enrollment
(January 1, 1975–October 1, 1976), the average age of the study
participants was 44 y and 65% of cohort members were male.
Since enrollment, study participants have undergone 21 detailed
interviews every 1–3 y regarding PUVA use, use of other psoriasis
treatments, and the development of skin tumors and other health
outcomes. Subjects were followed until date of death. For those
subjects who withdrew from the study or were lost, follow-up
ended with the date of last interview or the date of last reported
tumor, whichever was later. Specific methods of follow-up and
other features of this cohort have been described in detail in pre-
vious reports (Melski et al, 1977; Stern et al, 1998) and online. The
current report includes all data collected through the end of the
twenty-first cycle of follow-up, which concluded in 2003.
Tumors Only NMSC that had been diagnosed pathologically by a
board-certified pathologist, dermatopathologist, or dermatologist
were included in the analysis. SCC in situ and keratoacanthomas
were excluded from this analysis.
Classiﬁcation of exposures
UVB exposure UVB exposures were the sum of the number of
lifetime UVB treatments reported. We defined low-dose exposure
as o300 UVB treatment and high-dose exposure as X300 re-
ported treatments. In tests for trend, UVB was considered a con-
tinuous variable, whose value represented the total number of
lifetime UVB treatments up to that year (see online Methods).
PUVA exposure At each interview, subjects reported the number
of PUVA treatments received since last follow-up. In the data
analysis, PUVA was a time-dependent categorical variable defined
as the total number of treatments received up to that year and had
six categories of exposure: (1) o100 treatments, (2) 100–199
treatments, (3) 200–299 treatments, (4) 300–399 treatments, (5)
400–499 treatments, and (6) X500 treatments. In tests for trend,
PUVA was considered a continuous variable, whose value repre-
sented the total number of lifetime PUVA treatments up to that
year. Details regarding PUVA treatment protocols and dosages
used have been published in previous reports (Melski et al, 1977;
Stern et al, 1998).
Other risk factors Other important skin cancer risk factors such as
age, gender, skin type, geographic residence, and exposure to
other psoriasis therapies were also included in the analysis. Age
and year were considered continuous variables, whereas gender,
skin type, and geographic residence and other exposures were
considered categorical variables as defined in Tables II and IV, and
as further described in the online Methods section.
Subgroup analyses Knowing that the risk of NMSC increases
significantly with PUVA use and that PUVA use could potentially
overshadow the risks of UVB and other less strong risk modifiers,
in addition to analyzing the entire cohort, we stratified the cohort by
PUVA exposure and separately analyzed all patient years with total
PUVA exposureo100 treatments (defined as the ‘‘low-dose PUVA
group’’). We also separately analyzed the risk factors associated
with the development of tumors on chronically sun-exposed sites
and rare to intermittently sun-exposed sites in both the total cohort
and the low-dose PUVA group (see online Methods).
Statistical methods For every subject in the cohort, we calculat-
ed the person years (see online Methods) between enrollment and
date of death, date of last tumor, or date of last interview, which-
ever was last. The relative risk was defined as the incidence rate
among exposed divided by the incidence rate among non-ex-
posed, which is also known as the incident rate ratio (Hennekens
and Buring, 1987). The attributable risk was defined as the differ-
ence between observed incidence at the highest level of exposure
compared with the lowest level, and gives an estimate of the ab-
solute effect of the exposure.
Negative binomial regression models were used to quantify the
relation between exposure to UVB and other predictor variables
and the risk of NMSC, after adjusting for other potential confound-
ers (Glynn and Buring, 1996). Univariate analyses adjusted for age
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and year only. Multivariate analyses adjusted for each variable that
was statistically significant in the univariate model or was known to
be a risk modifier in this study population. Variables included in the
multivariate analysis were level of PUVA exposure, age, year since
enrollment, gender, skintype, geographic residence, year, and use
of methotrexate, tar, cyclosporin, and retinoids. To assess the risk
of skin cancer with UVB use, two primary endpoints were selected:
(1) the development of at least one SCC or BCC in a given year for
a given patient (i.e., incident tumors) and (2) the total number of
SCC or BCC in a given year for a given patient (i.e., total tumors).
By using incident tumors, we limit the influence of cohort members
who may be outliers, i.e. those rare individuals who develop a large
number of tumors per year. All analyses were performed on the
entire cohort and the low-dose PUVA group, for SCC and BCC
separately.
All statistical tests were two sided and were performed with
STATA 8.0 software (Stata Corp., College Station, Texas).
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